Rede D'Or São Luiz - Q1 2026 Earnings Analysis

Performance Highlights

Rede D'Or São Luiz reported consolidated gross revenue of R$15.5 billion in Q1 2026, a 10.0% increase year-over-year, with the hospital segment alone growing 15.6% YoY to R$9.2 billion, ahead of consensus expectations. Consolidated EBITDA surged 27.3% YoY to R$3.0 billion, expanding the EBITDA margin by 2.7 percentage points to 20.4%, while net income rose 13.9% YoY to R$1.2 billion.

The standout operating driver was surgical volume growth, with 145.6 thousand procedures performed in the quarter — up 11.9% YoY — alongside a 14.9% rise in complex surgeries and a 15.9% increase in oncology infusion volumes, pushing oncology gross revenue up 23.6% YoY. Supporting these trends, the LTM average ticket expanded 9.0% YoY to R$12,132, SulAmérica's health and dental membership surpassed 6.0 million beneficiaries (+11.4% YoY), and the consolidated insurance loss ratio improved 1.4 percentage points to 77.2%.

Management Outlook and Forward Catalysts

Management's expansion pipeline of approximately 30 projects totalling 2,702 beds — scheduled for delivery between 2026 and 2028 — signals that the business remains firmly in a capacity-investment phase, with greenfield and brownfield works actively underway across São Paulo, Rio de Janeiro, Brasília, and the Northeast. The Atlântica D'Or partnership with Bradesco Seguros, now operating six hospitals, further reinforces the strategy of deepening vertical integration between hospital services and insurance distribution.

The central investor debate for Q2 2026 centres on whether EBITDA margin expansion is sustainable as 2,702 new beds ramp up and financial expenses rise, with the net financial result deteriorating 41.8% YoY to negative R$744.2 million due to higher CDI rates and increased net debt. Bulls will watch for continued loss ratio improvement at SulAmérica and volume leverage from new bed capacity, while bears will focus on the pace of disallowance growth (+23.6% YoY), rising G&A at SulAmérica (+44.4% YoY), and RDOR3's 3.6% share price underperformance versus the IBOV's +16.3% gain in the quarter.